ArticleChild and adolescent psychiatry and mental health2025
Predicting five-year comorbid bipolar disorder after attention-deficit/hyperactivity disorder diagnosis: a population-based machine learning approach.
Article in Child and adolescent psychiatry and mental health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEarly detection and accurate prediction of bipolar disorders (BDs) comorbidity in individuals with attention-deficit/hyperactivity disorder (ADHD) are clinically critical. This study used machine-learning methods to identify features predictive of subsequent BD among patients initially diagnosed with ADHD.
methodsWe analyzed claims from the Taiwan National Health Insurance Research Database (2000–2013) and included patients aged ≥ 12 years with at least two diagnoses of ADHD. Predictor features included demographics (sex, age at ADHD onset), healthcare utilization (psychiatric outpatient visit counts), comorbidities (International Classification of Diseases–coded diagnoses), psychiatric medications (Anatomical Therapeutic Chemical–coded prescriptions), and family psychiatric history. All features were extracted from prespecified windows around the ADHD diagnosis date (index date). The primary outcome was a subsequent BD diagnosis. We trained an extreme gradient boosting (XGBoost) classifier and tuned hyperparameters via grid search to maximize the area under the receiver operating characteristic curve (AUROC). Feature importance was interpreted with Shapley additive explanations (SHAP).
resultsAmong 15,093 eligible patients, 266 (2%) developed BD during follow-up. The model achieved a ROC-AUC of 0.90 and a precision–recall AUC of 0.59; accuracy was 98%, specificity 99%, sensitivity 50%, and positive predictive value 43%. Twelve leading predictors emerged. The strongest behavioral signal was sparse psychiatric visits before ADHD diagnosis followed by frequent visits afterward (SHAP = 0.27 and 0.66, respectively). Core demographic risks were older age at ADHD onset (SHAP = 0.26) and male sex (SHAP = 0.08). Medication pattern included pre-diagnosis short-acting benzodiazepines (SHAP = 0.07) and post-diagnosis exposure to anticonvulsant mood stabilizers (SHAP = 0.34), “-dones” (SHAP = 0.06) and “-pines” (SHAP = 0.05) antipsychotics, selective serotonin-reuptake inhibitors (SHAP = 0.06), and Z-drugs (SHAP = 0.05). Protective features were having offspring with schizophrenia-spectrum disorders (SHAP = 0.11) and fewer new-onset upper-respiratory infections after ADHD diagnosis (SHAP = 0.06).
conclusionsLeveraging nationwide real-world data, we built a machine-learning model to predict subsequent comorbid BD in patients with ADHD. The identified clinical and medication prescribing profiles can alert clinicians to patients at heightened risk, facilitating earlier monitoring and timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.